mRNA’s next trick? Reprogramming off-the-shelf cell therapies for cancer and autoimmune diseases
A handful of biotechs, including Moderna, are betting that simple infusions with mRNA could supercharge immune cells to fight cancer and other diseases in what would be a fresh take on CAR-T cell therapies.
Instead of collecting a patient’s immune cells, engineering them in the lab, and reinfusing them — an intensive process that requires chemotherapy and comes with an array of side effects — these companies hope they can use mRNA to simplify the process while delivering the same benefits of current cell therapies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.